FATE - Fate Therapeutics Inc Stock Price, Fair Value and News

4.21USD+0.06 (+1.45%)Market Closed

Market Summary

USD4.21+0.06

Market Closed

1.45%

FATE Alerts

Big fall in earnings (Y/Y)

Losses in recent quarter

FATE Stock Price

View Fullscreen

FATE RSI Chart

FATE Valuation

Market Cap

472.4M

Price/Earnings (Trailing)

-2.49

Price/Sales (Trailing)

7.44

Price/Free Cashflow

-3.38

FATE Price/Sales (Trailing)

FATE Profitability

Return on Equity

-44.6%

Return on Assets

-33.35%

Free Cashflow Yield

-29.59%

FATE Fundamentals

FATE Revenue

Revenue (TTM)

63.5M

Rev. Growth (Yr)

-96.22%

Rev. Growth (Qtr)

-13.79%

FATE Earnings

Earnings (TTM)

-190.1M

Earnings Growth (Yr)

-154.25%

Earnings Growth (Qtr)

-8.8%

Breaking Down FATE Revenue

Last 7 days

-1.7%

Last 30 days

-28.1%

Last 90 days

-35.0%

Trailing 12 Months

-16.5%

How does FATE drawdown profile look like?

FATE Financial Health

Current Ratio

8.69

Debt/Equity

0.02

Debt/Cashflow

-14.44

FATE Investor Care

Shares Dilution (1Y)

15.70%

Diluted EPS (TTM)

-1.92

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	136.9M	119.3M	106.2M	63.5M
2022	63.1M	68.3M	69.0M	96.3M
2021	40.1M	48.0M	54.7M	55.8M
2020	10.6M	13.2M	18.3M	31.4M
2019	6.3M	8.1M	9.5M	10.7M
2018	4.1M	4.1M	4.1M	4.7M
2017	4.1M	4.1M	4.1M	4.1M
2016	3.8M	4.5M	4.5M	4.4M
2015	0	828.0K	1.6M	2.4M
2013	2.7M	1.9M	1.6M	971.0K
2012	1.5M	1.9M	2.3M	2.7M
2011	0	0	0	1.2M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Fate Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 04, 2024	dulac edward j iii	sold	-19,013	7.77	-2,447	chief financial officer
Jan 29, 2024	dulac edward j iii	sold	-9,245	5.00	-1,849	chief financial officer
Jan 09, 2024	tahl cindy	sold	-47,519	4.37	-10,874	general counsel and secretary
Jan 09, 2024	valamehr bahram	sold	-49,367	4.38	-11,271	chief r&d officer
Jan 09, 2024	wolchko j scott	sold	-62,888	4.37	-14,391	president and ceo
Jan 09, 2024	dulac edward j iii	sold	-30,712	4.37	-7,028	chief financial officer
Jan 02, 2024	dulac edward j iii	sold	-18,966	3.66	-5,182	chief financial officer
Dec 26, 2023	redmile group, llc	bought	166,024	3.72	44,630	-
Dec 26, 2023	redmile group, llc	sold	-6,157,980	3.72	-1,655,370	-
Dec 18, 2023	dulac edward j iii	sold	-5,547	3.5	-1,585	chief financial officer

Which funds bought or sold FATE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	ROYCE & ASSOCIATES LP	reduced	-59.56	-82,820	318,549	-%
May 13, 2024	FMR LLC	reduced	-12.2	787,460	1,876,440	-%
May 13, 2024	NEUBERGER BERMAN GROUP LLC	sold off	-100	-39,782	-	-%
May 13, 2024	XTX Topco Ltd	new	-	127,628	127,628	0.02%
May 13, 2024	NATIONAL BANK OF CANADA /FI/	reduced	-94.29	-24,198	1,632	-%
May 13, 2024	CANADA LIFE ASSURANCE Co	added	17.08	46,000	82,000	-%
May 13, 2024	Rafferty Asset Management, LLC	new	-	5,355,680	5,355,680	0.02%
May 13, 2024	Balyasny Asset Management L.P.	sold off	-100	-148,987	-	-%
May 13, 2024	Ameritas Investment Partners, Inc.	unchanged	-	30,089	61,348	-%
May 13, 2024	Dunhill Financial, LLC	unchanged	-	11,448	23,341	0.02%

Are Funds Buying or Selling FATE?

Are funds buying FATE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FATE

No. of Funds

Unveiling Fate Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 25, 2024	redmile group, llc	14.9%	17,619,095	SC 13D/A
Feb 13, 2024	vanguard group inc	9.43%	9,293,363	SC 13G/A
Feb 12, 2024	boxer capital, llc	6.3%	6,171,000	SC 13G
Feb 09, 2024	capital world investors	0.0%	0	SC 13G/A
Jan 25, 2024	point72 asset management, l.p.	4.8%	4,730,700	SC 13G
Jan 24, 2024	blackrock inc.	11.4%	11,212,816	SC 13G/A
Jan 22, 2024	state street corp	1.89%	1,861,919	SC 13G/A
Dec 28, 2023	redmile group, llc	14.9%	15,049,839	SC 13D/A
Oct 10, 2023	state street corp	2.31%	2,271,925	SC 13G/A
May 10, 2023	state street corp	14.24%	13,989,432	SC 13G/A

Recent SEC filings of Fate Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 09, 2024	8-K	Current Report
May 02, 2024	424B3	Prospectus Filed
Apr 29, 2024	EFFECT	EFFECT
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 18, 2024	S-3	S-3
Apr 16, 2024	PRE 14A	PRE 14A

Peers (Alternatives to Fate Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.2B	6.8B	19.54%	-2.80%	-8.24	7.18	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.91	4.73	60.38%	-34.49%
NVAX	1.9B	996.6M	206.31%	55.15%	-4.75	1.9	-26.66%	65.49%
CRBP	456.3M	881.7K	5.07%	336.18%	-13.52	481.06	-77.61%	33.36%
INO	297.2M	4.9M	3.08%	29.79%	-2.38	61.07	-54.97%	48.23%
IBIO	16.2M	2.1M	-10.40%	79.21%	-0.7	7.61	-13.45%	69.54%

Fate Therapeutics Inc News

Latest updates

Fate Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-100.0%	-	1,676	1,944	933	58,980	44,356	14,981	18,549	18,414	17,068	14,225	13,412	11,142	15,896	7,558	5,465	2,515	2,802	2,429	2,817	2,632
Operating Expenses	6.5%	52,993	49,751	53,223	63,498	87,572	108,775	101,372	101,658	92,881	86,450	68,848	60,191	57,352	49,295	39,045	34,172	37,007	31,880	29,548	26,901	23,078
S&GA Expenses	-100.0%	-	17,935	18,948	22,622	21,943	21,584	21,555	20,351	20,742	16,936	15,718	12,168	12,500	10,313	8,351	7,503	7,729	6,671	6,346	5,270	5,350
R&D Expenses	1.0%	32,138	31,816	34,275	40,876	65,629	87,191	79,817	81,307	72,139	69,515	53,130	48,023	44,852	38,982	30,694	26,669	29,278	25,209	23,202	21,631	17,728
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	538	400	409	405
Net Income	-8.8%	-48,004	-44,122	-45,170	-52,755	-18,881	-56,363	-83,563	-76,105	-65,690	-68,621	-43,308	-55,133	-45,089	-53,099	-58,684	-28,072	-33,520	-28,302	-26,609	-23,478	-19,760
Net Income Margin	-18.1%	-2.99*	-2.53*	-1.63*	-1.77*	-1.72*	-2.93*	-4.26*	-3.72*	-3.69*	-3.80*	-3.60*	-4.42*	-	-	-	-	-	-	-	-	-
Free Cashflow	9.2%	-33,436	-36,818	-38,838	-30,692	-32,068	-82,066	-63,723	-63,288	-74,697	-88,662	-48,110	-45,725	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	12.6%	570	506	544	585	630	706	749	807	858	921	985	1,016	1,046	622	626	654	322	302	340	200	221
Current Assets	19.0%	394	332	364	392	438	502	535	599	599	633	694	713	804	494	497	540	208	227	306	165	186
Cash Equivalents	189.8%	121	42.00	33.00	47.00	42.00	61.00	82.00	55.00	65.00	134	129	77.00	106	167	349	433	83.00	100	250	71.00	183
Net PPE	-4.9%	92.00	97.00	102	106	109	110	109	103	98.00	92.00	75.00	59.00	48.00	32.00	21.00	16.00	12.00	11.00	10.00	9.00	8.00
Current Liabilities	16.1%	45.00	39.00	41.00	45.00	49.00	114	104	92.00	78.00	81.00	92.00	106	95.00	86.00	54.00	45.00	25.00	28.00	41.00	29.00	29.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9.00	11.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.00	5.00	4.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9.00	11.00
Shareholder's Equity	15.7%	426	368	403	438	477	484	518	580	633	679	730	752	790	384	424	474	219	245	268	128	146
Retained Earnings	-4.0%	-1,259	-1,211	-1,167	-1,122	-1,069	-1,050	-994	-910	-834	-769	-700	-657	-602	-556	-503	-445	-417	-383	-355	-328	-305
Additional Paid-In Capital	6.7%	1,686	1,580	1,571	1,561	1,548	1,536	1,516	1,495	1,471	1,449	1,431	1,409	1,392	941	928	919	636	628	623	456	451
Shares Outstanding	15.4%	114	99.00	99.00	99.00	98.00	97.00	97.00	97.00	96.00	96.00	95.00	94.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	462,000	-	-	-	2,340,000	-	-	-	6,960	-	-	-	2,490	-	-	-	1,056	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	9.0%	-33.35	-36.64	-38.27	-28.49	-28.86	-75.39	-55.05	-53.16	-64.61	-70.29	-33.37	-32.11	-27.10	-20.66	-30.73	39.00	-26.67	-25.53	-19.84	-20.31	-17.49
Share Based Compensation	-100.0%	-	9.00	10.00	13.00	11.00	19.00	19.00	21.00	19.00	15.00	14.00	13.00	13.00	9.00	8.00	7.00	7.00	5.00	5.00	4.00	4.00
Cashflow From Investing	-61.8%	17.00	45.00	25.00	33.00	9.00	53.00	80.00	40.00	-7.03	71.00	78.00	-1.37	-471	-166	-54.14	35.00	24.00	-110	36.00	-91.98	9.00
Cashflow From Financing	53148.9%	95.00	-0.18	-	0.00	0.00	2.00	1.00	3.00	3.00	3.00	8.00	4.00	438	5.00	1.00	276	1.00	-13.72	162	1.00	1.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

FATE Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Collaboration revenue	$ 1,925	$ 58,980
Type of Revenue [Extensible List]	us-gaap:LicenseMember	us-gaap:LicenseMember
Operating expenses:
Research and development	$ 32,138	$ 65,629
General and administrative	20,855	21,943
Total operating expenses	52,993	87,572
Loss from operations	(51,068)	(28,592)
Other income (expense):
Interest income	4,149	3,694
Change in fair value of stock price appreciation milestones	(1,394)	1,718
Other income	309	4,299
Total other income	3,064	9,711
Net loss	(48,004)	(18,881)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities, net	(209)	1,208
Comprehensive loss	$ (48,213)	$ (17,673)
Net loss per common share, basic	$ (0.47)	$ (0.19)
Net loss per common share, diluted	$ (0.47)	$ (0.19)
Weighted-average common shares used to compute basic net loss per share	101,104,345	98,054,687
Weighted-average common shares used to compute diluted net loss per share	101,104,345	98,054,687

FATE Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 121,322	$ 41,870
Accounts receivable	858	1,826
Short-term investments	262,222	273,305
Prepaid expenses and other current assets	9,973	14,539
Total current assets	394,375	331,540
Long-term investments	7,595	980
Property and equipment, net	92,116	96,836
Operating lease right-of-use assets	60,620	61,675
Restricted cash	15,177	15,177
Other assets	9	9
Total assets	569,892	506,217
Current liabilities:
Accounts payable	6,765	4,719
Accrued expenses	32,043	27,514
Deferred revenue	159	685
Operating lease liabilities, current portion	6,402	6,176
Total current liabilities	45,369	39,094
Operating lease liabilities, net of current portion	95,668	97,360
Stock price appreciation milestones	2,740	1,346
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; authorized shares - 5,000,000 at March 31, 2024 and December 31, 2023; Class A Convertible Preferred shares issued and outstanding - 2,761,108 at March 31, 2024 and December 31, 2023	3	3
Common stock, $0.001 par value; authorized shares - 250,000,000 at March 31, 2024 and December 31, 2023; issued and outstanding - 113,798,942 at March 31, 2024 and 98,627,076 at December 31, 2023	114	99
Additional paid-in capital	1,685,928	1,580,032
Accumulated other comprehensive income (loss)	(194)	15
Accumulated deficit	(1,259,736)	(1,211,732)
Total stockholders’ equity	426,115	368,417
Total liabilities and stockholders’ equity	$ 569,892	$ 506,217

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

CEO	Mr. J. Scott Wolchko
WEBSITE	fatetherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	551

Fate Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Fate Therapeutics Inc? What does FATE stand for in stocks?

FATE is the stock ticker symbol of Fate Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Fate Therapeutics Inc (FATE)?

As of Mon May 13 2024, market cap of Fate Therapeutics Inc is 472.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FATE stock?

You can check FATE's fair value in chart for subscribers.

What is the fair value of FATE stock?

You can check FATE's fair value in chart for subscribers. The fair value of Fate Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Fate Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FATE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Fate Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether FATE is over valued or under valued. Whether Fate Therapeutics Inc is cheap or expensive depends on the assumptions which impact Fate Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FATE.

What is Fate Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, FATE's PE ratio (Price to Earnings) is -2.49 and Price to Sales (PS) ratio is 7.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FATE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Fate Therapeutics Inc's stock?

In the past 10 years, Fate Therapeutics Inc has provided -0.046 (multiply by 100 for percentage) rate of return.